Nykredit A S Purchases Shares of 282,407 Stryker Corporation $SYK

Key Points

• Nykredit A S acquired 282,407 Stryker shares during the second quarter, valued at approximately $88.9 million; institutional investors collectively own 77.09% of the company.
• Stryker exceeded quarterly earnings expectations, reporting $3.69 in EPS and $6.59 billion in revenue, with revenue up 9.4% year over year. The company issued fiscal 2026 EPS guidance of $14.95–$15.10.
• The stock traded at $280.36, down 1.5%, while analysts maintained a “Moderate Buy” consensus with an average price target of $378.75. Stryker also declared a quarterly dividend of $0.88 per share, although insiders sold approximately $118.2 million of stock during the last quarter.

Nykredit A S acquired a new position in shares of Stryker Corporation (NYSE:SYK - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 282,407 shares of the medical technology company's stock, valued at approximately $88,913,000. Nykredit A S owned about 0.07% of Stryker at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of SYK. Amundi increased its holdings in shares of Stryker by 18.3% in the second quarter. Amundi now owns 1,246,353 shares of the medical technology company's stock valued at $392,402,000 after purchasing an additional 192,447 shares in the last quarter. Rakuten Investment Management Inc. acquired a new position in Stryker during the 2nd quarter worth $18,646,000. Bank of America Corp DE acquired a new position in Stryker during the 2nd quarter worth $1,404,284,000. Royal Bank of Canada boosted its position in Stryker by 6.5% in the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company's stock valued at $1,075,552,000 after buying an additional 199,863 shares during the last quarter. Finally, Rathbones Group PLC increased its stake in shares of Stryker by 647.9% in the 4th quarter. Rathbones Group PLC now owns 219,265 shares of the medical technology company's stock valued at $77,065,000 after buying an additional 189,948 shares during the period. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Trading Down 1.5%

NYSE:SYK opened at $280.36 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 1-year low of $267.00 and a 1-year high of $392.55. The firm has a market capitalization of $107.54 billion, a price-to-earnings ratio of 29.05, a PEG ratio of 1.79 and a beta of 0.76. The business's 50-day moving average price is $321.03 and its two-hundred day moving average price is $323.18.

Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts expect that Stryker Corporation will post 15 earnings per share for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Insider Activity

In related news, Director Ronda Stryker sold 300,000 shares of the company's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares in the company, valued at $773,031,862.50. This represents a 11.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Debra King sold 826 shares of the firm's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 351,267 shares of company stock valued at $118,197,701 in the last quarter. Company insiders own 4.60% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SYK. Evercore set a $350.00 target price on Stryker in a research report on Monday, July 6th. Truist Financial lifted their price objective on Stryker from $330.00 to $340.00 and gave the stock a "hold" rating in a research report on Friday, July 31st. Wolfe Research cut Stryker from an "outperform" rating to a "peer perform" rating in a report on Thursday, August 13th. JPMorgan Chase & Co. cut their target price on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. Finally, UBS Group began coverage on shares of Stryker in a research note on Tuesday, July 28th. They issued a "buy" rating and a $400.00 target price on the stock. Eighteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $378.75.

Stryker Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker's principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.